About: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 1997 (uk) article scientifique publié en 1997 (fr) im Juli 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunetu de 1997 (ast) scientific article published on 01 July 1997 (en)
publication date	wds:Q73494793-A01252F3-3B3C-4F99-B6E6-9D14B66973B1
publication date	1997-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73494793-2620BAE0-D283-4BF5-A5CE-F2EBE33B8293
language of work or name	English
author name string	wds:Q73494793-228E6DB8-5D6B-4702-B0F0-D4E969A387AC wds:Q73494793-2C61085F-5909-4D09-BD84-BBB4B585ED05 wds:Q73494793-93D01FE7-A0A3-4B0A-A036-53B032294A2F wds:Q73494793-A08474E3-F231-4C90-8C5F-4DA0B2DCF40D wds:Q73494793-E8CF70C5-9C83-4E75-B46F-D478F697E3EB wds:Q73494793-F9B90F62-5464-483F-B5D2-2C0F3E33045C wds:Q73494793-FA1357F0-BFE7-41A2-92E1-E9EB3B96DBCD
author name string	P J Loehrer D Trump K J Propert L H Einhorn E D Crawford D Raghavan S B Saxman
rdfs:label	Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study (en) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study (nl)
skos:prefLabel	Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study (en) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study (nl)
name	Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study (en) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study (nl)
author	wds:Q73494793-54E386C8-FD33-4B0F-8F4C-A7B0BDC349F1
author	Ian F. Tannock
title	wds:Q73494793-98586901-D617-4958-93B0-591A0C5317D5
title	Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study (en)
page(s)	wds:Q73494793-36F6F963-7062-46F8-A99B-E9A8CF8C9FF8
page(s)	2564-2569
instance of	wds:Q73494793-AFDD1610-939C-4B69-884E-41AAC8E2C3B6
instance of	scholarly article
main subject	wds:Q73494793-0ADC4328-3CD4-4025-9E2B-46F1733FD70A wds:Q73494793-316B96D9-5F7F-4442-933C-541EE140BFA4 wds:Q73494793-C0BE8F35-F8C0-4CFB-886C-D1B83B1FA6BE wds:Q73494793-D989FB39-3786-425A-BD69-F5537E7BD275
main subject	wd:Q18936 vinblastine wd:Q422232 cisplatin
PubMed ID	wds:Q73494793-BE0C99D0-CB1A-4883-80D9-993B23CDA225
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9215826
PubMed ID	9215826
published in	wds:Q73494793-2DC3A0BD-F948-44E1-9909-CADCF744BFB5
published in	Journal of Clinical Oncology
issue	wds:Q73494793-1BE2EE7A-4AA9-4FBE-82F1-1955C9C62926
volume	wds:Q73494793-C477818F-1BB5-4678-899E-6F3377C4BBFF
issue	7
volume	15
DOI	wds:Q73494793-DA467800-0EAF-45EB-8CB0-F58B2117CFB0
DOI	http://dx.doi.org/10.1200/JCO.1997.15.7.2564
DOI	10.1200/JCO.1997.15.7.2564
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73494793
is cites work of	Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Management of bladder cancer: current and emerging strategies Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma Current understanding of the biology of advanced bladder cancer First- and second-line therapy for metastatic urothelial carcinoma of the bladder Bladder reconstruction: The past, present and future. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. The systemic treatment of advanced and metastatic bladder cancer. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium Surgery and adjunctive chemotherapy for invasive bladder cancer Heat shock protein 90 targeting therapy: state of the art and future perspective Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract Gemcitabine in locally advanced and/or metastatic bladder cancer The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software